Pipeline Keenova eyes Xiaflex as first drug for plantar fibromatosis PharmaphorumKeenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet.Rare DiseaseRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Keenova is hoping that its Xiaflex drug can become the first approved therapy for plantar fibromatosis, a debilitating condition affecting the feet. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA freezes CRL trove as ‘radical transparency’ push hits speedbump Related Stories Pipeline AlzeCure enters collaboration agreement with QuantumCell ApS for NeuroRestore project pharminent July 1, 2026 Pipeline Biogen trims Apellis pipeline and R&D team after $5.6bn takeover pharminent June 29, 2026 Pipeline Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms pharminent June 26, 2026
